Pediatric Brain Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | Abbott, Moleculin Biotech, Cellectar Biosciences, Oncoceutics, Chimerix, Kazia Therapeutics, Laminar Pharma

The Pediatric Brain Tumors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Brain Tumors pipeline products will significantly revolutionize the Pediatric Brain Tumors market dynamics.

DelveInsight's "Pediatric Brain Tumors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pediatric Brain Tumors, historical and forecasted epidemiology as well as the Pediatric Brain Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pediatric Brain Tumors market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Pediatric Brain Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pediatric Brain Tumors Market Insights
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pediatric Brain Tumors Market Report:
• The Pediatric Brain Tumors market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, BCB-276, a CAR T-cell therapy targeting B7-H3, received Breakthrough Therapy Designation from the FDA for the treatment of pediatric diffuse intrinsic pontine glioma (DIPG). This designation, similar to the RMAT (Regenerative Medicine Advanced Therapy) designation, is available for cell therapies, tissue-engineered products, and human cell and tissue-based treatments aimed at addressing serious or life-threatening conditions.
• In April 2025, BrainChild Bio's investigational CAR-T therapy, BCB-276, which targets B7-H3 for the treatment of diffuse intrinsic pontine glioma (DIPG)-a rare pediatric brain tumor-has been granted Breakthrough Therapy Designation by the FDA. This designation is based on data from the Phase 1 BrainChild-03 trial (NCT04185038), conducted by BrainChild's academic collaborator, Seattle Children's, which showed an overall survival benefit in patients with brain tumors. The company now plans to launch a pivotal Phase 2 trial to support a future biologics license application (BLA) for BCB-276 in children and young adults with DIPG.
• In January 2025, BrainChild Bio, Inc., a clinical-stage biotech company focused on CAR T-cell therapies for central nervous system (CNS) tumors, has unveiled its clinical development strategy for BCB-276-its lead autologous CAR T-cell therapy targeting the immune checkpoint B7-H3-for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and currently incurable pediatric brain cancer.
• As per the study by Johnson et al., there are over 100 distinct histological types of CNS tumors, each with varying incidence rates depending on age and subtype. The occurrence of childhood CNS tumors differs across countries, ranging from 1.12 to 5.14 cases per 100,000 individuals, with the United States reporting the highest incidence.
• According to Plus Therapeutics' March 2024 corporate presentation, the company plans to begin enrollment in the ReSPECT-PBC Phase I trial of Rhenium Obisbemeda for pediatric patients with high-grade glioma and ependymoma.
• In April 2024, The US FDA gave approval to Day One Biopharmaceuticals' OJEMDA (tovorafenib), a novel treatment for pediatric low-grade glioma (pLGG).
• According to the study published by Johnson et al., there are >100 different histological subtypes of CNS tumors with the incidence of each varying by age and histologic subtype. Childhood CNS tumor incidence varies by country from 1.12-5.14 cases per 100,000 persons with the highest incidence in the United States
• As per Cancer.Net, about 3,540 children under the age of 15 were diagnosed with a brain or CNS tumor in 2020
• According to American Cancer Society, brain and spinal cord tumors are the second most common cancers in children (after leukemia). They account for about 1 out of 4 childhood cancers. More than 4,000 brain and spinal cord tumors are diagnosed each year in children and teens
• Key Pediatric Brain Tumors Companies: Moleculin Biotech, Cellectar Biosciences, Oncoceutics, Chimerix, Kazia Therapeutics, Laminar Pharmaceuticals, Abbott, AbbVie Inc., Akorn, Inc., Agios, Inc., Baxter, Bayer AG, Epizyme, Inc., Novar, tis AG, Mylan N.V., and others
• Key Pediatric Brain Tumors Therapies: LP561A1, GDC-008, ONC201, CLR-131, WP1066, and others
• The Pediatric Brain Tumors epidemiology based on gender analyzed that pediatric brain tumors are more common in males, however, this varies by histologic type

Pediatric Brain Tumors Overview
Pediatric central nervous system (CNS) tumors are the second most common childhood malignancy and the most common solid tumor in children. Approximately 4,000 children and adolescents in the US are diagnosed with primary brain tumors each year. Primary brain tumors start in the brain and generally do not spread outside the brain tissue.

Get a Free sample for the Pediatric Brain Tumors Market Report:
https://www.delveinsight.com/report-store/pediatric-brain-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pediatric Brain Tumors Market
The dynamics of the Pediatric Brain Tumors market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Pediatric Brain Tumors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pediatric Brain Tumors Epidemiology Segmentation:
The Pediatric Brain Tumors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Pediatric Brain Tumors
• Prevalent Cases of Pediatric Brain Tumors by severity
• Gender-specific Prevalence of Pediatric Brain Tumors
• Diagnosed Cases of Episodic and Chronic Pediatric Brain Tumors

Download the report to understand which factors are driving Pediatric Brain Tumors epidemiology trends @ Pediatric Brain Tumors Epidemiological Insights
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pediatric Brain Tumors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Brain Tumors market or expected to get launched during the study period. The analysis covers Pediatric Brain Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pediatric Brain Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Pediatric Brain Tumors treatment, visit @ Pediatric Brain Tumors Medications
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pediatric Brain Tumors Therapies and Key Companies
• AFINITOR (everolimus): Abbott
• LP561A1: Laminar Pharmaceuticals
• GDC-008: Kazia Therapeutics
• ONC201: Oncoceutics/ Chimerix
• CLR-131: Cellectar Biosciences
• WP1066: Moleculin Biotech

Pediatric Brain Tumors Market Strengths
• Children with brain tumors generally have a better prognosis than adults with a similar condition
• Increased public awareness, improved access to health services, and awareness with disease understanding are identified on screening and diagnosis, thereby acting as a market driver

Pediatric Brain Tumors Market Opportunities
• Currently, the pipeline of pediatric brain tumors has drugs in mid- and early phase of development. This provides a huge opportunity for the advent of innovative and effective novel therapies and targeted treatments

Scope of the Pediatric Brain Tumors Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pediatric Brain Tumors Companies: Moleculin Biotech, Cellectar Biosciences, Oncoceutics, Chimerix, Kazia TherapeuticsLaminar Pharmaceuticals, Abbott, AbbVie Inc., Akorn, Inc., Agios, Inc., Baxter, Bayer AG, Epizyme, Inc., Novar, tis AG, Mylan N.V., and others
• Key Pediatric Brain Tumors Therapies: LP561A1, GDC-008, ONC201, CLR-131, WP1066, and others
• Pediatric Brain Tumors Therapeutic Assessment: Pediatric Brain Tumors current marketed and Pediatric Brain Tumors emerging therapies
• Pediatric Brain Tumors Market Dynamics: Pediatric Brain Tumors market drivers and Pediatric Brain Tumors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pediatric Brain Tumors Unmet Needs, KOL's views, Analyst's views, Pediatric Brain Tumors Market Access and Reimbursement

Discover more about therapies set to grab major Pediatric Brain Tumors market share @ Pediatric Brain Tumors market forecast
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pediatric Brain Tumors Market Report Introduction
2. Executive Summary for Pediatric Brain Tumors
3. SWOT analysis of Pediatric Brain Tumors
4. Pediatric Brain Tumors Patient Share (%) Overview at a Glance
5. Pediatric Brain Tumors Market Overview at a Glance
6. Pediatric Brain Tumors Disease Background and Overview
7. Pediatric Brain Tumors Epidemiology and Patient Population
8. Country-Specific Patient Population of Pediatric Brain Tumors
9. Pediatric Brain Tumors Current Treatment and Medical Practices
10. Pediatric Brain Tumors Unmet Needs
11. Pediatric Brain Tumors Emerging Therapies
12. Pediatric Brain Tumors Market Outlook
13. Country-Wise Pediatric Brain Tumors Market Analysis (2020-2034)
14. Pediatric Brain Tumors Market Access and Reimbursement of Therapies
15. Pediatric Brain Tumors Market Drivers
16. Pediatric Brain Tumors Market Barriers
17. Pediatric Brain Tumors Appendix
18. Pediatric Brain Tumors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports:
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.